Clinical trial

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

NCT04740034

Study summary

ClinicalTrials.gov

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AMG 340 Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-04-29

PhasePHASE1

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

AMG 340DRUG

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

New YorkNew York, United States1 PhiladelphiaPennsylvania, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 DenverColorado, United States1 New OrleansLouisiana, United States1 SarasotaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04740034 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.